Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Operating Income (2016 - 2026)

Cytosorbents filings provide 15 years of Operating Income readings, the most recent being $8.6 million for Q4 2025.

  • On a quarterly basis, Operating Income rose 352.08% to $8.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.8 million, a 89.02% increase, with the full-year FY2025 number at -$1.8 million, up 89.02% from a year prior.
  • Operating Income hit $8.6 million in Q4 2025 for Cytosorbents, up from -$2.9 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $8.6 million in Q4 2025 to a low of -$9.6 million in Q4 2021.
  • Median Operating Income over the past 5 years was -$5.2 million (2021), compared with a mean of -$5.2 million.
  • Biggest five-year swings in Operating Income: tumbled 262.98% in 2021 and later skyrocketed 352.08% in 2025.
  • Cytosorbents' Operating Income stood at -$9.6 million in 2021, then soared by 33.52% to -$6.4 million in 2022, then crashed by 48.01% to -$9.4 million in 2023, then soared by 63.91% to -$3.4 million in 2024, then skyrocketed by 352.08% to $8.6 million in 2025.
  • The last three reported values for Operating Income were $8.6 million (Q4 2025), -$2.9 million (Q3 2025), and -$3.6 million (Q2 2025) per Business Quant data.